Monashee Investment Management LLC Buys Shares of 160,336 Immatics N.V. $IMTX

Monashee Investment Management LLC acquired a new position in Immatics N.V. (NASDAQ:IMTX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 160,336 shares of the company’s stock, valued at approximately $1,684,000. Monashee Investment Management LLC owned about 0.13% of Immatics as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. SG Americas Securities LLC bought a new stake in shares of Immatics in the 4th quarter worth approximately $2,189,000. Baker BROS. Advisors LP lifted its holdings in shares of Immatics by 18.9% in the 3rd quarter. Baker BROS. Advisors LP now owns 12,094,094 shares of the company’s stock worth $103,042,000 after acquiring an additional 1,925,193 shares during the last quarter. Jefferies Financial Group Inc. bought a new stake in shares of Immatics in the 3rd quarter worth approximately $10,181,000. Aberdeen Group plc lifted its holdings in shares of Immatics by 9.7% in the 3rd quarter. Aberdeen Group plc now owns 789,446 shares of the company’s stock worth $6,726,000 after acquiring an additional 69,860 shares during the last quarter. Finally, TD Asset Management Inc lifted its holdings in shares of Immatics by 33.1% in the 3rd quarter. TD Asset Management Inc now owns 383,804 shares of the company’s stock worth $3,270,000 after acquiring an additional 95,548 shares during the last quarter. 64.41% of the stock is currently owned by institutional investors.

Immatics Stock Up 2.1%

Shares of NASDAQ IMTX opened at $9.06 on Friday. Immatics N.V. has a 52 week low of $5.05 and a 52 week high of $12.41. The firm’s fifty day moving average is $10.80 and its 200 day moving average is $10.26. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -4.55 and a beta of 1.30.

Immatics (NASDAQ:IMTX) last issued its earnings results on Tuesday, May 12th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.08). Immatics had a negative return on equity of 47.36% and a negative net margin of 572.35%.The firm had revenue of $8.81 million during the quarter, compared to analysts’ expectations of $9.79 million. Equities research analysts anticipate that Immatics N.V. will post -1.67 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. TD Cowen assumed coverage on shares of Immatics in a report on Tuesday, April 28th. They issued a “buy” rating for the company. Chardan Capital restated a “buy” rating and issued a $25.00 price objective on shares of Immatics in a report on Tuesday, May 19th. Mizuho set a $25.00 price objective on shares of Immatics in a report on Thursday, February 19th. Wall Street Zen lowered shares of Immatics from a “hold” rating to a “sell” rating in a report on Saturday, May 2nd. Finally, Jefferies Financial Group assumed coverage on shares of Immatics in a report on Monday, March 16th. They issued a “buy” rating and a $18.00 price objective for the company. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $20.80.

Immatics Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.